Atogepant for migraine.
Citation: Drugs of Today. 58(8):399-405, 2022 Aug.PMID: 35983926Department: Headache Fellowship | MedStar Georgetown University Hospital/MedStar Washington Hospital CenterForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Calcitonin Gene-Related Peptide Receptor Antagonists | *Migraine Disorders | Analgesics/tu [Therapeutic Use] | Calcitonin Gene-Related Peptide | Calcitonin Gene-Related Peptide Receptor Antagonists/tu [Therapeutic Use] | Humans | Migraine Disorders/dt [Drug Therapy] | Piperidines | Pyridines | Pyrroles | Spiro CompoundsYear: 2022ISSN:- 1699-3993
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 35983926 | Available | 35983926 |
Atogepant is a selective oral, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist that has been approved for preventive treatment of migraine. CGRP is a neuropeptide involved in vasodilation and cerebrovascular regulation. CGRP is the most potent vasoactive constituent of the cerebrovascular trigeminal neuronal system and has a key role in migraine. Medications targeting CGRP are being used as migraine preventive and abortive treatments. Copyright 2022 Clarivate.
English